ImmuneOnco Biopharmaceuticals (Shanghai) (1541.HK) Earnings Analysis
ImmuneOnco Biopharmaceuticals (Shanghai) (1541.HK) next reports earnings on 2026-09-01. Trailing P/E -5.46.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 1541.HK next report earnings?
| Next earnings date | 2026-09-01 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | n/a |
1541.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-08-25 | -0.40987 HKD | n/a | n/a | n/a |
| 2024-12-31 | -0.42002 HKD | n/a | n/a | n/a |
1541.HK valuation and analyst view
| Trailing P/E | -5.46 |
|---|---|
| Trailing EPS | -0.51203 HKD |
| Price / book | 1.55 |
| Dividend yield | 0.00% |
| Market cap | 1.43B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is ImmuneOnco Biopharmaceuticals (Shanghai) (1541.HK)'s next earnings date?
ImmuneOnco Biopharmaceuticals (Shanghai) is next scheduled to report on 2026-09-01.
Did 1541.HK beat earnings last quarter?
Consensus estimate data was not available for 1541.HK's 2025-08-25 report.
What is 1541.HK's current P/E ratio and EPS?
1541.HK trades at a trailing P/E of -5.46 on trailing EPS of -0.5120321092817438 HKD.
What do analysts rate 1541.HK?
1541.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.